EssilorLuxottica has expanded its Essilor Stellest myopia management platform, unveiling a suite of new technologies designed to support earlier intervention and improve clinical outcomes for children at risk of myopia.
The announcement was made at the China International Import Expo (CIIE) in Shanghai on 6 November.
Building on more than four decades of research and innovation, the updated platform includes Essilor Stellest 2.0 spectacle lenses, an evidence-based pre-myopia solution, and Essilor Stellest Smartglasses. The expanded product range aims to address the needs of the 740 million children projected to develop myopia by 2050.
The new Essilor Stellest 2.0 lenses have been shown to deliver significantly higher efficacy in slowing the axial elongation that drives myopic progression. According to a 12-month prospective, randomised, double-masked contralateral crossover clinical trial of 50 children in Singapore, the advanced design generates a stronger optical signal with double the mean optical power.
The launch builds on the success of the original Essilor Stellest lens, the first FDA-authorised spectacle lens clinically proven to slow myopia progression in children. Stellest 2.0 is now available in Greater China, with rollout to other key markets planned from 2026. The lenses are not currently available in the US.
In a step toward early intervention, EssilorLuxottica has introduced Essilor Stellest plano pair lenses, designed for children aged 6–12 who are at risk of developing myopia. Clinical research shows that delaying myopia onset by just one year can provide benefits comparable to more than two years of slowed progression.
One of the world’s first independent randomised controlled trials on plano lenses found that children who wore the lenses for more than 30 hours a week experienced slower axial elongation. The plano pair lenses are available in Greater China, with additional markets to follow from 2026, and are not currently available in the US.
EssilorLuxottica also debuted the Essilor Stellest Smartglasses, the brand’s first smart eyewear developed specifically for myopia management. Equipped with Essilor Stellest lenses, the device tracks wearing time and patterns, provides behavioural insights and supports compliance – a key factor influencing treatment effectiveness. The smartglasses will be available in mainland China from Q1 2026.
EssilorLuxottica chairman and CEO Francesco Milleri and deputy CEO Paul du Saillant said the expansion reflects the company’s commitment to transforming myopia care through med-tech innovation.
“By combining advanced lens technology with smart features, we enable early intervention, promote healthy wearing habits, and accelerate progress in slowing myopia progression in children. Our purpose is clear: turning evidence into action and technology into empowerment,” they said.
“By working closely with industry partners and advancing evidence-based innovation, we aim to deliver even more groundbreaking solutions, reinforcing our commitment to advancing eye health for the next generation.”
